Breast cancer-specific survival in patients with lymph node-positive hormone receptor-positive invasive breast cancer and Oncotype DX Recurrence Score results in the SEER database

被引：0
|
作者：
Megan C. Roberts
Dave P. Miller
Steven Shak
Valentina I. Petkov
机构：
[1] National Cancer Institute,
[2] Genomic Health Inc.,undefined
来源：
Breast Cancer Research and Treatment | 2017年 / 163卷
关键词：
Breast cancer; Disease-specific survival; Lymph node-positive; Oncotype DX; Recurrence Score; SEER;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：303 / 310
页数：7
相关论文
共 50 条
  • [41] Effect of Involved Lymph Node Size on Cancer-Specific Mortality in Women With Node-Positive Breast Cancer
    Rose, B.
    Jiang, W.
    Punglia, R. S.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2014, 90 : S274 - S274
  • [42] Using Oncotype DX breast recurrence score® assay to define the role of neoadjuvant endocrine therapy in early-stage hormone receptor-positive breast cancer
    Caitlin Taylor
    Jane Meisel
    Aimee J. Foreman
    Christy Russell
    Dipankar Bandyopadhyay
    Xiaoyan Deng
    Lisa Floyd
    Amelia Zelnak
    Harry Bear
    Ruth O’Regan
    Breast Cancer Research and Treatment, 2023, 199 : 91 - 98
  • [43] Effect of 21-gene recurrence score results on treatment recommendations in patients age 65 and older with lymph node-positive, estrogen receptor-positive breast cancer.
    Oratz, R.
    Chao, C.
    Skrzypczak, S.
    Ory, C.
    Broder, M.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [44] Using Oncotype DX breast recurrence score® assay to define the role of neoadjuvant endocrine therapy in early-stage hormone receptor-positive breast cancer
    Taylor, Caitlin
    Meisel, Jane
    Foreman, Aimee J.
    Russell, Christy
    Bandyopadhyay, Dipankar
    Deng, Xiaoyan
    Floyd, Lisa
    Zelnak, Amelia
    Bear, Harry
    O'Regan, Ruth
    BREAST CANCER RESEARCH AND TREATMENT, 2023, 199 (01) : 91 - 98
  • [45] Trend and survival benefit of Oncotype DX use among female hormone receptor-positive breast cancer patients in 17 SEER registries, 2004-2015
    Zhang, Lu
    Hsieh, Mei-Chin
    Petkov, Valentina
    Yu, Qingzhao
    Chiu, Yu-wen
    Wu, Xiao-Cheng
    BREAST CANCER RESEARCH AND TREATMENT, 2020, 180 (02) : 491 - 501
  • [46] Prediction of recurrence with the Oncotype DX recurrence score in node-positive, HR-positive, breast cancer patients treated with adjuvant chemotherapy: Results from PACS01 trial.
    Penault-Llorca, Frederique Madeleine
    Filleron, Thomas
    Asselain, Bernard
    Baehner, Frederick L.
    Fumoleau, Pierre
    Lacroix-Triki, Magali
    Butler, Steven M.
    Jamshidian, Farid
    Cherbavaz, Diana B.
    Shak, Steven
    Roca, Lise
    Sagan, Christine
    Lemonnier, J.
    Martin, Anne-Laure
    Roche, Henri Hubert
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [47] Factors Associated With Node-positive Disease in Estrogen Receptor-Positive Breast Cancer Patients
    Gallagher, Julia
    Elleson, Kelly M.
    Englander, Katherine
    Chintapally, Neha
    Sun, Weihong
    Whiting, Junmin
    Laronga, Christine
    Lee, Marie Catherine
    JOURNAL OF SURGICAL RESEARCH, 2024, 295 : 327 - 331
  • [48] Prognostic impact of HER2-low expression according to the oncotype Dx recurrence score in hormone receptor-positive early breast cancer
    Mutai, R.
    Barkan, T.
    Moore, A.
    Sarfaty, M.
    Stemmer, S.
    Shohat, T.
    Yerushlami, R.
    Goldvaser, H.
    ANNALS OF ONCOLOGY, 2021, 32 : S424 - S424
  • [49] Association of Chemotherapy With Survival in Elderly Patients With Multiple Comorbidities and Estrogen Receptor-Positive, Node-Positive Breast Cancer
    Tamirisa, Nina
    Lin, Heather
    Shen, Yu
    Shaitelman, Simona F.
    Sri Karuturi, Meghan
    Giordano, Sharon H.
    Babiera, Gildy
    Bedrosian, Isabelle
    JAMA ONCOLOGY, 2020, 6 (10) : 1548 - 1554
  • [50] Is there a role for the oncotype DX breast recurrence score genomic assay in estrogen receptor-low positive breast cancer?
    Giordano, Julia
    McGrath, Monica
    Harrison, Beth
    Kantor, Olga
    Vora, Halley
    Burstein, Harold J.
    Tolaney, Sara M.
    King, Tari A.
    Mittendorf, Elizabeth A.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
12345